{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:09:53Z","timestamp":1789560593259,"version":"build-2803163510"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.cyto.2026.157213","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T22:56:44Z","timestamp":1789081004000},"page":"157213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma"],"prefix":"10.1016","volume":"207","author":[{"given":"Phoebe Elizabeth","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyuan","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Saja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Rushworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf Michael","family":"Zwacka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.cyto.2026.157213_bb0005","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.cyto.2026.157213_bb0010","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.cyto.2026.157213_bb0015","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.clml.2024.03.008","article-title":"SOHO state of the art updates and next questions: diagnosis and Management of Monoclonal Gammopathy of undetermined significance and Smoldering multiple myeloma","volume":"24","author":"Schmidt","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"10","key":"10.1016\/j.cyto.2026.157213_bb0020","doi-asserted-by":"crossref","first-page":"5371","DOI":"10.1007\/s00277-025-06581-x","article-title":"Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study","volume":"104","author":"Della Pepa","year":"2025","journal-title":"Ann. Hematol."},{"issue":"17","key":"10.1016\/j.cyto.2026.157213_bb0025","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","article-title":"Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"391","author":"Facon","year":"2024","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1016\/j.cyto.2026.157213_bb0030","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.cyto.2026.157213_bb0035","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.cyto.2026.157213_bb0040","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"20","key":"10.1016\/j.cyto.2026.157213_bb0045","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"issue":"6159","key":"10.1016\/j.cyto.2026.157213_bb0050","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/332083a0","article-title":"Autocrine generation and requirement of BSF-2\/IL-6 for human multiple myelomas","volume":"332","author":"Kawano","year":"1988","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0055","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood.V73.2.517.517","article-title":"Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6","volume":"73","author":"Klein","year":"1989","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.cyto.2026.157213_bb0060","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.cyto.2026.157213_bb0065","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0092-8674(90)90411-7","article-title":"Molecular cloning and expression of an IL-6 signal transducer, gp130","volume":"63","author":"Hibi","year":"1990","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0092-8674(94)90333-6","article-title":"Cytokine signal transduction","volume":"76","author":"Kishimoto","year":"1994","journal-title":"Cell"},{"issue":"6\u20137","key":"10.1016\/j.cyto.2026.157213_bb0075","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.ejcb.2010.10.007","article-title":"The soluble interleukin 6 receptor: generation and role in inflammation and cancer","volume":"90","author":"Chalaris","year":"2011","journal-title":"Eur. J. Cell Biol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1042\/bj3000281","article-title":"Soluble receptors for cytokines and growth factors: generation and biological function","volume":"300","author":"Rose-John","year":"1994","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0085","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/1043-4666(92)90043-Q","article-title":"Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor","volume":"4","author":"Lust","year":"1992","journal-title":"Cytokine"},{"issue":"43","key":"10.1016\/j.cyto.2026.157213_bb0090","doi-asserted-by":"crossref","first-page":"26059","DOI":"10.1074\/jbc.M115.649509","article-title":"Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by A disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles","volume":"290","author":"Schumacher","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.cyto.2026.157213_bb0095","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.cyto.2026.157213_bb0100","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni.3632","article-title":"Trans-presentation of IL-6 by dendritic cells is required for the priming of pathogenic TH17 cells","volume":"18","author":"Heink","year":"2017","journal-title":"Nat. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1046\/j.1365-2141.1996.d01-1470.x","article-title":"Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma. Finnish Leukaemia Group","volume":"92","author":"Pulkki","year":"1996","journal-title":"Br. J. Haematol."},{"issue":"10","key":"10.1016\/j.cyto.2026.157213_bb0110","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/(SICI)1097-0142(19980515)82:10<1860::AID-CNCR7>3.0.CO;2-R","article-title":"The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma","volume":"82","author":"Stasi","year":"1998","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cyto.2026.157213_bb0115","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/eji.1830230408","article-title":"Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy","volume":"23","author":"Gaillard","year":"1993","journal-title":"Eur. J. Immunol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(91)90198-O","article-title":"A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry","volume":"139","author":"Nicoletti","year":"1991","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.cyto.2026.157213_bb0125","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1006\/cyto.1996.0055","article-title":"A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA","volume":"8","author":"Oh","year":"1996","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.cyto.2026.157213_bb0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.11.5.613","article-title":"The IL-6\/sIL-6R complex as a novel target for therapeutic approaches","volume":"11","author":"Rose-John","year":"2007","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.cyto.2026.157213_bb0135","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cyto.2014.05.024","article-title":"Interleukin-6 and its receptors: a highly regulated and dynamic system","volume":"70","author":"Wolf","year":"2014","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0140","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nbt0297-142","article-title":"Bioactive designer cytokine for human hematopoietic progenitor cell expansion","volume":"15","author":"Fischer","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.cyto.2026.157213_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cyto.2018.07.014","article-title":"STAT3 isoforms: alternative fates in cancer?","volume":"118","author":"Aigner","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.cyto.2026.157213_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.112048","article-title":"Post-translational modifications of Stat3: the state of the art","volume":"135","author":"Chen","year":"2025","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.cyto.2026.157213_bb0155","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/75068","article-title":"Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo","volume":"6","author":"Atreya","year":"2000","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.cyto.2026.157213_bb0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1046\/j.1432-1327.2001.01867.x","article-title":"Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses","volume":"268","author":"Jostock","year":"2001","journal-title":"Eur. J. Biochem."},{"issue":"3","key":"10.1016\/j.cyto.2026.157213_bb0165","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood-2007-07-102137","article-title":"Transgenic blockade of interleukin 6 transsignaling abrogates inflammation","volume":"111","author":"Rabe","year":"2008","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.cyto.2026.157213_bb0170","doi-asserted-by":"crossref","first-page":"6762","DOI":"10.1074\/jbc.RA117.001163","article-title":"The balance of interleukin (IL)-6, IL-6.soluble IL-6 receptor (sIL-6R), and IL-6.sIL-6R.sgp130 complexes allows simultaneous classic and trans-signaling","volume":"293","author":"Baran","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.cyto.2026.157213_bb0175","first-page":"203","article-title":"Serum sIL-6R levels as prognostic factor in multiple myeloma","volume":"46","author":"Kami\u0144ska","year":"2015","journal-title":"Acta Haematol. Pol."},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0180","first-page":"71","article-title":"Serum interleukin-6 and interleukin-6 receptor levels in patients with multiple myeloma","volume":"28","author":"Kyriakou","year":"1997","journal-title":"Haematologia"},{"issue":"9","key":"10.1016\/j.cyto.2026.157213_bb0185","first-page":"2693","article-title":"Myeloma cells release soluble interleukin-6Ralpha in relation to disease progression by two distinct mechanisms: alternative splicing and proteolytic cleavage","volume":"5","author":"Thabard","year":"1999","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.cyto.2026.157213_bb0190","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.cyto.2026.157213_bb0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ajh.10304","article-title":"Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity","volume":"72","author":"Alexandrakis","year":"2003","journal-title":"Am. J. Hematol."},{"issue":"5","key":"10.1016\/j.cyto.2026.157213_bb0200","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood.V74.5.1704.1704","article-title":"Increased plasma levels of interleukin-6 in sepsis","volume":"74","author":"Hack","year":"1989","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cyto.2026.157213_bb0205","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/eji.1830181122","article-title":"Excessive production of interleukin 6\/B cell stimulatory factor-2 in rheumatoid arthritis","volume":"18","author":"Hirano","year":"1988","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.cyto.2026.157213_bb0210","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.canlet.2021.06.017","article-title":"Fas-threshold signalling in MSCs promotes pancreatic cancer progression and metastasis","volume":"519","author":"Mohr","year":"2021","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.cyto.2026.157213_bb0215","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016295","article-title":"IL-6 in inflammation, immunity, and disease","volume":"6","author":"Tanaka","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157213_bb0220","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1084\/jem.169.1.333","article-title":"The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome","volume":"169","author":"Waage","year":"1989","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.cyto.2026.157213_bb0225","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/sj.onc.1201253","article-title":"Dexamethasone induces apoptosis of multiple myeloma cells in a JNK\/SAP kinase independent mechanism","volume":"15","author":"Chauhan","year":"1997","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.cyto.2026.157213_bb0230","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.leu.2402022","article-title":"The bone marrow stromal microenvironment influences myeloma therapeutic response in vitro","volume":"15","author":"Cheung","year":"2001","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.cyto.2026.157213_bb0235","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1038\/nrd.2018.45","article-title":"Interleukin-6: designing specific therapeutics for a complex cytokine","volume":"17","author":"Garbers","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.cyto.2026.157213_bb0240","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.cyto.2026.157213_bb0245","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajh.23868","article-title":"A phase 2, randomized, double-blind, placebo-controlled study of siltuximab (anti-IL-6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma","volume":"90","author":"Orlowski","year":"2015","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.cyto.2026.157213_bb0250","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/bjh.12266","article-title":"A phase 2 multicentre study of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma","volume":"161","author":"Voorhees","year":"2013","journal-title":"Br. J. Haematol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626001080?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466626001080?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T11:47:31Z","timestamp":1789559251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466626001080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"alternative-id":["S1043466626001080"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157213","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-derived mesenchymal stromal cells establish an IL-6 axis that marks progression from smouldering to active multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2026.157213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157213"}}